Earnings Deep Dives
-
Procter & Gamble (PG) Q3 2026 Earnings Results
Read more: Procter & Gamble (PG) Q3 2026 Earnings ResultsProcter & Gamble’s latest results highlight a business that remains operationally resilient, but increasingly constrained by a shifting consumer environment and structural margin pressure. On the surface, fiscal Q3 2026 delivered a solid set of numbers. Net sales increased 7% year-on-year to $21.2 billion, with organic growth of 3% driven by a combination of volume…
-
NextEra Energy (NEE) Q1 2026 Earnings Results
Read more: NextEra Energy (NEE) Q1 2026 Earnings ResultsNextEra Energy (NEE) continues to present one of the more interesting valuation debates in the market today. It sits at the intersection of utility stability and structural growth, and the numbers reflect that tension clearly. At a current price of 96.25 and a trailing PE of 24, the stock screens expensive on the surface. However,…
-
Tesla (TSLA) Q1 2026 Earnings Results
Read more: Tesla (TSLA) Q1 2026 Earnings ResultsTesla’s (TSLA) Q1 2026 earnings highlight a business in transition. While the company continues to invest aggressively in future growth drivers, the latest quarter underscores ongoing pressure in its core automotive segment. Revenue declined modestly year over year, with total revenue down approximately 3%, while automotive revenue fell by around 10%. Vehicle deliveries also weakened,…
-
Vertiv (VRT) Q1 2026 Earnings Results
Read more: Vertiv (VRT) Q1 2026 Earnings ResultsVertiv delivered a standout first quarter, reinforcing its position as one of the key beneficiaries of the accelerating buildout in AI and data center infrastructure. However, while the fundamentals remain exceptionally strong, the stock increasingly reflects a market that has already priced in near-perfect execution. The headline numbers were impressive. Revenue grew approximately 30% year…
-
Intuitive Surgical Q1 2026 Earnings Results
Read more: Intuitive Surgical Q1 2026 Earnings ResultsRecent results from Intuitive Surgical reinforce what the market already understands: this is one of the highest-quality businesses in healthcare technology. Revenue grew 23% year-on-year to $2.77 billion, driven primarily by procedure growth rather than one-off system sales. Procedures increased 17%, with da Vinci procedures up 16% and Ion procedures up 39%. This is critical,…
-
RTX Q1 2026 Earnings Results
Read more: RTX Q1 2026 Earnings ResultsRTX delivered a strong start to 2026, with first-quarter results that reinforce its position as a high-quality aerospace and defense compounder, though not without some caveats for shareholders. The headline numbers were impressive. Revenue rose 9% year over year to $22.1 billion, with 10% organic growth across all three business segments. Even more notable was…
- Rummu provides data, analysis, and tools for research purposes only. The information presented does not constitute financial advice, a recommendation, or an offer to buy or sell any securities. It does not take into account individual objectives, financial situations, or needs. You are solely responsible for your own investment decisions.